Therapeutic drug monitoring of patients on risperidone depot

Nordic Journal of Psychiatry

Volumn 59, Issue 1, 2005, Pages 51-55

  Nesvåg, Ragnar ^a   Tanum, Lars ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Atypical; Depot; Risperidone; Schizophrenia; Therapeutic drug monitoring

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; CITALOPRAM; CLOZAPINE; DRUG METABOLITE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; INJECTION; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT MONITORING; PATIENT SELECTION; REFERENCE VALUE; RETROSPECTIVE STUDY; STANDARD; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 16344377056     PISSN: 08039488     EISSN: None     Source Type: Journal    
DOI: 10.1080/08039480510018832     Document Type: Article

References (12)

1. Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology 2000;148:3-15.
2. Love RC. Strategies for increasing treatment compliance: The role of long-acting antipsychotics. Am J Health-Syst Pharm 2002;59(Suppl 8):10-5.
3. Kane JM, Aguglia E, Altamura AC, Gutierrez JLA, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66.
4. Remington GJ, Adams ME. Depot neuroleptic therapy: Clinical considerations. Can J Psychiatry 1995;40(3 Suppl 1):5-9.
5. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
6. Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq Z, Saleh BT. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin 2003;19:298-305.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
8. Risperdal Consta TM. Product Monograph. Janssen Cilag; 2002.
9. Marder SR, Hubbard JW, Van Putten T, Midha KK. Pharmacokinetics of long-acting injectable neuroleptic drugs: Clinical implications. Psychopharmacology 1989;98:433-9.
10. Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors. Ther Drug Monit 1999;21:105-15.
11. Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985;10:315-33.
12. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227-63.